Can Pragmatic Trials Bend the Antineoplastic Therapy Cost Curve?

Maurie Markman, MD
Published: Wednesday, Feb 26, 2020
Maurie Markman, MD, editor in chief, is president of Medicine and Science at Cancer Treatment Centers of America and clinical professor of medicine, Drexel University College of Medicine, Seattle Cancer Care Alliance

Maurie Markman, MD

Clinical trials in oncology serve several purposes. Phase I studies address dosing, toxicity, and increasingly preliminary evidence of therapeutic efficacy; phase II studies more critically demonstrate clinical utility and adverse effects; and phase III randomized studies more definitively compare 2 or more approaches in seeking an answer to a clinical question. These efforts ultimately help define and, potentially, modify the “standard of care” in routine cancer management. Finally, so-called phase IV studies are frequently employed by industry sponsors to obtain additional regulatory agency approvals or, alternatively, oncology drug compendium (eg, National Comprehensive Cancer Network) listing as acceptable strategies in particular clinical settings.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication